GraphoLearn Reading Intervention for Dyslexia
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the GraphoLearn reading intervention treatment for dyslexia?
Research shows that GraphoLearn, a computer game designed to help with reading, improved reading skills in children at risk for dyslexia by enhancing their ability to read made-up words and quickly name objects. Another study found that a version of GraphoGame helped young children at risk for dyslexia improve their letter knowledge and word decoding skills, giving them a head start in early literacy.12345
How is the GraphoLearn reading intervention treatment different from other treatments for dyslexia?
GraphoLearn is unique because it is a computer-based game that helps children with dyslexia by training them to match speech sounds with written letters, making it both engaging and educational. Unlike traditional methods, it uses technology to provide intensive, personalized practice, and has been adapted for use in various languages and educational contexts worldwide.12367
What is the purpose of this trial?
The current project will carry out a large-scale, randomized controlled trial (RCT) to examine the effectiveness of a home-administered technology-based treatment for reading disability (GraphoLearn) in a diagnostically diverse children with reading disability (ages 6.0-10.00). To accomplish this rapidly and with minimal cost, the experimenters will leverage the Healthy Brain Network \[HBN\], an ongoing study of mental health and learning disorders in children ages 5.0-21.0 whose family have one or more concerns about behavior and/or learning (target n = 10,000; current enrollment = 3000+). The HBN includes comprehensive psychiatric, cognitive, electroencephalogram \[EEG\] and multimodal magnetic resonance imaging \[MRI\] characterizations for all participants, providing the present work rich data to build from. The present work will recruit 450 children (ages 6.0-10.0) with reading difficulty from the HBN.In order to evaluate GraphoLearn effectiveness the experimenters will compare reading (and related language skills) before and after a 12-week GraphoLearn reading intervention relative to an active (math) control. The experimenters also assess the stability of the reading gains by including a 12 week retention period ( with pre and post retention assessment).The experimenters hypothesize that they will observe significant gains in reading (and related language) skills relative to the math control conditions, but that these gains will be variable and predicted by participant and environment level factors (predictive models are explored under Aim 2).This evaluation will involve a 3 to 4 visit between groups longitudinal study with cross over elements to evaluate GraphoLearn in struggling readers ages 6-10 using and pre-post behavioral and EEG assessment.
Research Team
Nicole Landi, PhD
Principal Investigator
University of Connecticut
Eligibility Criteria
This trial is for children aged 6 to 10 who are part of the Healthy Brain Network, have reading difficulties as shown by specific test scores, and can speak English natively. They must be able to use a keyboard or mouse and not have severe vision or hearing issues, certain psychiatric conditions like psychosis or major depression, nor moderate to severe autism.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a 12-week GraphoLearn reading intervention or an active math control
Retention
Participants' reading gains are assessed for stability during a retention period
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- GraphoLearn reading intervention
- Vektor math control intervention
GraphoLearn reading intervention is already approved in European Union, United States, Canada for the following indications:
- Reading disability
- Dyslexia
- Reading disability
- Dyslexia
- Reading disability
- Dyslexia
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Connecticut
Lead Sponsor
Haskins Laboratories
Collaborator
Child Mind Institute
Collaborator
Georgia State University
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator